That was great advice George.How did you know we would hit $4 again? You are brilliant.

Encouraging news.lets hope it sticks.

My jokes=not ok,but all other garbage here’s fine?GTFOOH

Baker Bros emailed me...they have been reading my posts about sales concerns and insurance coverage concerns and they agree and have been dumping their shares. Seriously;)

Pre-COVID sales is irrelevant.Need to look at quarter-to-quarter and week-to-week now.

Now that is some value added feedback.Keep-up the great analysis.

Agreed,other drugs are selling fine.Insurance coverage needs improvement and advertising needs to increase.

AMRN was$20 before we knew low sales growth was an issue.Everyone assumed Vascepa would fly off the shelves and sales would explode, and that is not the case.The sales environment has changed for the foreseeable future.

So your concern is PRs effect on short-term price fluctuations? Unless you are day trading, what does it really matter? News is news, regardless of day released,and the market will price it in eventually. As you can see, the only news that matters now is the trial outcome. We’ve been stuck at around 7 for a while now.

What makes a Friday PR release “horrid timing”?

Depends on insurance coverage and Tx growth.Needs improvement or price wont reach the old highs, even with trial win.

If I’m wrong I make money.Extreme optimism is blinding and has cost folks a lot of money. Arguing against my AMRN position keeps me honest and eyes open.

Someone still needs to pay for the prescriptions and doctors visits. You need a WILLING and ABLE consumer. It doesn’t matter how great of a drug we think it is. Or how many studies that prove a great benefit of taking it.

Could - I agree on multiple points

Without a willing and able consumer,we have nothing.

Nope...consider consumer demographics,COVID longterm economic impact...”pay for food/car/home/rent or Vascepa?” Its much more complex. Out of those millions of people who have temporarily and permanently lost jobs, and who have now lost the unemployment supplement, there are a lot of potential Vascepa consumers. Not to mention those who have reduced incomes but are still employed. Doctors visits are not free. This will take years to recover from. Unless insurance makes Vascepa nearly free, I’m expecting more of the same lackluster sales performance for years. I hope I’m wrong, which is why I’m in leaps.

True,but AMRN still must sell Vascepa,and lackluster sales growth will suppress the share price.

Smart move.Trial means nothing without revenue/script growth.Europe will take much longer to materialize now too. Might want to move those bully risk reversals out even further in time.

Can someone explain how AMRN shareprice ever increases with lagging revenue and low script growth? This is going to turn out to be a much longer term play than I was hoping for.

Post-February(pandemic)is the new normal.AMRN must do better in today’s environment. They need to sell a lot more, in the US and/or ROW or this stock is going nowhere.

Got Math? 86,444(TRxToday)-81,064(TRxFeb7)=5380.That’s 6.6%growth in 6months.With ads,and COVIDs not going away.We won’t see +20 for a long time, even with trial win. Those numbers better start going up.

No scrip growth=no shareprice appreciation,regardless of trial outcome.AMRN downside risk is much greater than the upside potential right now.

Ay caramba!Share price will now languish for years,even with AC decision in favor of AMRN. Revenue is no bueno.

Hello Everyone! My name is Jorge. I am an Amarin investor and a former professional trader who now trades stocks and options for a living. I am excited to engage with you all about Amarin. Have a good evening.